Mixed Deck — All BCACP Topics Flashcards

Which of the following best describes a key benefit of the BCACP credential to patients?

Answer: It assures patients that the pharmacist has demonstrated advanced competence in ambulatory care

BCACP signals to patients and employers that the pharmacist has met rigorous standards for ambulatory care expertise.

A patient on rosuvastatin 20 mg develops unexplained muscle pain. CK is 12,000 U/L. What is the most appropriate action?

Answer: Discontinue rosuvastatin immediately

Markedly elevated CK (>10× ULN) with muscle symptoms indicates myopathy/rhabdomyolysis and requires immediate statin discontinuation.

A pharmacy director is negotiating a value-based contract with a payer. Which metric would BEST demonstrate the pharmacy team's impact on total cost of care?

Answer: Medication adherence rates for chronic disease medications

Medication adherence is directly linked to reduced hospitalizations, ER visits, and downstream costs, making it a powerful value-based metric.

Researchers wish to determine if exposure to a certain workplace chemical is associated with the development of a rare form of cancer. They identify a group of individuals with the cancer (cases) and a similar group without the cancer (controls). They then look back in time, using work history records, to determine the rate of chemical exposure in each group. Which study design does this describe?

Answer: Case-Control Study

This describes a case-control study. This design starts by identifying individuals with the outcome of interest (cases) and a comparable group without the outcome (controls). It then looks retrospectively to compare the frequency of exposure to a risk factor in both groups. A prospective cohort study would start with exposed and unexposed groups and follow them forward in time to see who develops the disease.

A patient taking phenelzine (an MAOI) for treatment-resistant depression requests tramadol for pain. What is the MOST serious risk of this combination?

Answer: Serotonin syndrome

Tramadol inhibits serotonin reuptake and combined with an MAOI creates a potentially life-threatening serotonin syndrome.

A clinical trial for a new heart failure medication reports a statistically significant reduction in its primary composite endpoint of 'cardiovascular death, hospitalization for heart failure, or urgent heart failure visit.' An analysis of the individual components reveals the benefit was driven almost exclusively by a reduction in urgent heart failure visits, with no significant difference in CV death or hospitalizations. What is the most appropriate clinical interpretation?

Answer: The benefit of the drug is primarily related to reducing less severe events like urgent heart failure visits.

When evaluating a composite endpoint, it is crucial to examine the individual components to understand the true effect of the intervention. A significant result for the composite does not automatically apply to all its components. In this case, the benefit was driven by the softest, least severe endpoint, so the most accurate interpretation is that the drug's main effect is on reducing urgent HF visits, not necessarily on the more severe outcomes of hospitalization or death.

A patient on warfarin begins fluconazole therapy for a vaginal yeast infection. What is the expected pharmacokinetic effect?

Answer: Increased warfarin levels due to CYP2C9 inhibition

Fluconazole is a potent CYP2C9 inhibitor that dramatically increases warfarin exposure, requiring INR monitoring and likely dose reduction.

A pharmacist is performing a chart review to identify patients overdue for pneumococcal vaccination. This activity is best described as:

Answer: Population health outreach using a registry

Using patient registries or chart reviews to proactively identify care gaps is a core population health strategy.

Which concept in health behavior theory suggests that a patient's belief in their ability to successfully take medication predicts adherence?

Answer: Self-efficacy from social cognitive theory

Self-efficacy, the belief in one's capacity to perform a specific behavior, is a strong predictor of medication adherence.

Which PCSK9 inhibitor is FDA-approved as a twice-yearly subcutaneous injection for LDL reduction?

Answer: Inclisiran

Inclisiran is an siRNA that inhibits PCSK9 synthesis and is dosed subcutaneously at baseline, 3 months, then every 6 months.

Which of the following scenarios demonstrates appropriate use of the BCACP credential after certification?

Answer: Using 'BCACP' after one's name on professional documents once BPS officially awards the credential

The BCACP designation should only be used professionally once BPS officially awards and confirms the credential.

A patient with T2DM is taking saxagliptin and develops lower extremity edema and shortness of breath. Which adverse effect of saxagliptin is most likely responsible?

Answer: Increased risk of heart failure hospitalization

The SAVOR-TIMI trial showed saxagliptin was associated with a significantly increased risk of heart failure hospitalization, an FDA-labeled warning.

A patient starting warfarin therapy has a CYP2C9 *2/*3 genotype. What clinical implication does this have?

Answer: Patient will require lower than average warfarin doses due to reduced enzyme activity

CYP2C9 *2 and *3 alleles encode enzymes with reduced activity, leading to decreased warfarin metabolism and lower dose requirements.

Which antihypertensive combination is generally AVOIDED due to risk of hyperkalemia, acute kidney injury, and hypotension?

Answer: ACE inhibitor + ARB

Dual RAAS blockade combining an ACE inhibitor with an ARB increases risk of hyperkalemia, AKI, and hypotension without additional CV benefit.

A pharmacist is reviewing medication adherence data using proportion of days covered (PDC). A patient's PDC for their antihypertensive is 0.72. How should this be interpreted?

Answer: The patient is non-adherent; PDC must be ≥0.80 for most HEDIS measures

Most HEDIS and quality measures define adherence as PDC ≥0.80; a PDC of 0.72 falls below this threshold, classifying the patient as non-adherent.

A patient with PTSD is not responding to sertraline. Which medication is the ONLY other FDA-approved pharmacotherapy specifically indicated for PTSD?

Answer: Paroxetine

Paroxetine (Paxil) is the only other FDA-approved medication for PTSD besides sertraline; venlafaxine and prazosin are used off-label.

A pharmacist is counseling a Spanish-speaking patient with limited English proficiency. What is the MOST appropriate approach?

Answer: Use a qualified medical interpreter or translated materials

Qualified medical interpreters or professionally translated materials ensure accurate communication and meet legal and ethical standards for patients with limited English proficiency.

A patient with chronic low back pain and depression is seeking pharmacological treatment that may address both conditions. Which non-opioid analgesic class has dual evidence for both chronic musculoskeletal pain and depression?

Answer: SNRIs (e.g., duloxetine)

SNRIs such as duloxetine (Cymbalta) are FDA-approved for both major depressive disorder and chronic musculoskeletal pain conditions including chronic low back pain, diabetic peripheral neuropathy, and fibromyalgia. This dual mechanism (norepinephrine and serotonin reuptake inhibition) provides analgesic and antidepressant effects. COX-2 inhibitors and topical diclofenac have analgesic but no antidepressant properties. Gabapentin treats neuropathic pain but is not approved for depression.

A patient newly diagnosed with T2DM asks whether he can reverse his diabetes through lifestyle changes. What is the most accurate pharmacist response?

Answer: Intensive lifestyle intervention can lead to remission (A1C <6.5% without medications) in some patients, especially early after diagnosis

Evidence from studies like the DiRECT trial shows intensive lifestyle intervention with significant weight loss can lead to T2DM remission, particularly when achieved early in the disease course.

A pharmacist is tasked with reducing hospital readmission rates for patients recently discharged with heart failure. Which of the following interventions is MOST appropriate for improving outcomes across this population?

Answer: Provide post-discharge medication reconciliation and education

Heart failure patients are at high risk for readmission, often due to medication discrepancies, poor adherence, or lack of understanding of their complex regimens post-discharge. Pharmacist-led medication reconciliation and comprehensive education at discharge significantly reduce medication errors, improve patient understanding, and enhance adherence. This directly leads to lower readmission rates and better outcomes for this vulnerable population.